Announcement of The Consolidated Financial Report for The 4th Quarter of Year 2023
2024.3.8
Announcement of The Consolidated Financial Report for The 4th Quarter of Year 2023
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 17 | Date of announcement | 2024/03/08 | Time of announcement | 19:27:51 |
| Subject | Announcement of The Consolidated Financial Report for The 4th Quarter of Year 2023 | ||||
| Date of events | 2024/03/08 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2024/03/08 2.Date of the audit committee approved:2024/03/08 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2023/01/01~2023/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):5,505,542 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):3,282,130 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,372,433 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,419,465 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):1,118,601 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):1,128,509 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):4.54 11.Total assets end of the period (thousand NTD):9,874,909 12.Total liabilities end of the period (thousand NTD):3,368,767 13.Equity attributable to owners of parent end of the period (thousand NTD):5,941,340 14.Any other matters that need to be specified:None |
||||